Blog
RSS FeedPosted by Michael Wonder on 05 Oct 2016
Sitagliptin and sitagliptin with metformin hydrochloride in type 2 diabetes mellitus: additional benefit compared to sulphonylurea plus metformin hydrochloride
4 October 2016 - For other questions, an additional benefit has not been established. ...
Posted by Michael Wonder on 05 Oct 2016
Saxagliptin and saxagliptin with metformin hydrochloride in type 2 diabetes mellitus: additional clinical benefits still not there
4 October 2016 - Study evaluations unsuitable for statements about the positive or negative effects over comparative therapies. ...
Posted by Michael Wonder on 29 Sep 2016
FDA eyes new diabetes outcome measures
29 September 2016 - A recent FDA workshop brought new diabetes outcome measures to the table, focusing on patient-oriented outcome measures. ...
Posted by Michael Wonder on 22 Sep 2016
CADTH calls for patient input on a resubmission from NovoNordisk for Victoza (liraglutide)
21 September 2016 - CADTH is calling for patient input on a resubmission from Novo Nordisk for Victoza (liraglutide). ...
Posted by Michael Wonder on 21 Sep 2016
U.S. FDA approves Invokamet XR (canagliflozin with metformin hydrochloride extended-release) for the treatment of adults with type 2 diabetes
21 September 2016 - Newest Invokana (canagliflozin) plus metformin treatment provides unique formulation option for first-line therapy. ...
Posted by Michael Wonder on 05 Sep 2016
Xultophy (insulin degludec/liraglutide) receives European approval for use in adults with type 2 diabetes mellitus and moderate renal impairment
1 September 2016 - Novo Nordisk has announced that the European Commission has approved the expanded use of Xultophy (insulin degludec ...
Posted by Michael Wonder on 31 Aug 2016
Schedule of Pharmaceutical Benefits - 1 September 2016 update
1 September 2016 - The 1 September 2016 issue of the Schedule of Pharmaceutical Benefits sees a number of new ...
Posted by Michael Wonder on 30 Aug 2016
CADTH recommends the reimbursement of Invokamet (canagliflozin hemihydrate with metformin hydrochloride)
25 August 2016 - CADTH has published its final recommendation on the reimbursement of Invokamet in Canada. ...
Posted by Michael Wonder on 22 Aug 2016
Sanofi provides update on new drug application for investigational once-daily fixed-ratio combination of insulin glargine and lixisenatide
19 August 2016 - Sanofi announced today that it has submitted updated information on the pen delivery device as part ...
Posted by Michael Wonder on 14 Aug 2016
Diabetes breakthrough part of $70m PBS medicines listings
13 August 2016 - As many as 20,000 Australians living with Type 2 diabetes will find it easier and cheaper to ...
Posted by Michael Wonder on 14 Aug 2016
Type 2 diabetes boost: new treatment will save money and multiple injections
14 August 2016 - Thousands of Australians with type 2 diabetes mellitus will soon be able to have one injection a ...
Posted by Michael Wonder on 12 Aug 2016
Health Canada approves new indication for Jardiance (empagliflozin) tablets for adults with type 2 diabetes and established cardiovascular disease
11 August 2016 - Approval based on cardiovascular outcome clinical trial EMPA-REG OUTCOME, which demonstrated empagliflozin significantly reduced the incidence of ...
Posted by Michael Wonder on 11 Aug 2016
CADTH provides an update on its therapeutic review of new drugs for type 2 diabetes mellitus
10 August 2016 - CADTH is undertaking a project to assess the clinical and cost-effectiveness of new drugs for the treatment ...
Posted by Michael Wonder on 28 Jul 2016
FDA approves Adlyxin to treat type 2 diabetes
28 July 2016 - The U.S. FDA approved Adlyxin (lixisenatide), a once-daily injection to improve glycemic control (blood sugar levels), along ...
Posted by Michael Wonder on 27 Jul 2016
EMA publishes EPAR for Qtern (saxagliptin hydrochloride with dapagliflozin propanediol monohydrate)
27 July 2016 - The EMA has published an EPAR for AstraZeneca's Qtern. ...